Manifold Bio, a Boston, MA-based protein therapeutics company, raised $40M in Series A funding.
The round was led by Triatomic Capital with participation from Section 32, FPV Ventures, Horizons Ventures, Tencent, Playground Global, Fifty Years, and FAST. With this funding, Triatomic Capital founding partner Jeff Huber will join Manifold Bio’s board of directors. Huber was previously founder and CEO of Grail and co-founder of Google’s life sciences efforts.
The company intends to use the funds to advance its internal drug programs and expand its protein engineering platform to support additional programs and partnerships.
Founded by leading biological engineers from Harvard Medical School and the Wyss Institute CEO Gleb Kuznetsov, PhD, CSO Pierce Ogden, PhD, George Church, PhD, along with co-founder and Head of Business Development Shane Lofgren, Manifold Bio is a fully-integrated biotechnology company pursuing a pipeline of targeting-enhanced protein therapeutics. The company has built an in vivo biologics design platform powered by a novel protein barcoding technology. Using this platform, the company has initiated several internal programs focused in oncology.
FinSMEs
14/07/2022